ZYUS Life Sciences Corporation
ZLSCF
$0.59
-$0.0501-7.83%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.78% | -0.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.78% | -0.22% | |||
| Cost of Revenue | -95.88% | 2,296.33% | |||
| Gross Profit | 105.08% | -1,679.65% | |||
| SG&A Expenses | 15.76% | -19.80% | |||
| Depreciation & Amortization | -14.53% | 7.04% | |||
| Other Operating Expenses | -31.76% | 422.35% | |||
| Total Operating Expenses | -21.61% | 13.77% | |||
| Operating Income | 21.90% | -14.24% | |||
| Income Before Tax | 83.76% | -488.66% | |||
| Income Tax Expenses | -- | -11,541.60% | |||
| Earnings from Continuing Operations | 82.24% | -440.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 82.24% | -440.57% | |||
| EBIT | 21.90% | -14.24% | |||
| EBITDA | 32.41% | -31.19% | |||
| EPS Basic | 82.23% | -424.62% | |||
| Normalized Basic EPS | 19.16% | -14.80% | |||
| EPS Diluted | 82.24% | -424.87% | |||
| Normalized Diluted EPS | 19.16% | -14.80% | |||
| Average Basic Shares Outstanding | -0.02% | 3.04% | |||
| Average Diluted Shares Outstanding | -0.02% | 3.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||